Preimplantation Genetics Diagnosis Pgd Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Preimplantation Genetic Diagnosis (PGD) market, covering key insights, projections, and trends from 2023 to 2033. It explores the market dynamics, segmentation, regional performance, and the influence of technology in shaping the future of PGD.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $2.40 Billion |
| CAGR (2023-2033) | 9.5% |
| 2033 Market Size | $6.14 Billion |
| Top Companies | Illumina, Thermo Fisher Scientific, Natera, Gene by Gene |
| Last Modified Date | 15 Nov 2024 |
Preimplantation Genetics Diagnosis Pgd Market Report (2023 - 2033)
Preimplantation Genetics Diagnosis Pgd Market Overview
What is the Market Size & CAGR of Preimplantation Genetics Diagnosis Pgd market in 2023?
Preimplantation Genetics Diagnosis Pgd Industry Analysis
Preimplantation Genetics Diagnosis Pgd Market Segmentation and Scope
Request a custom research report for industry.
Preimplantation Genetics Diagnosis Pgd Market Analysis Report by Region
Europe Preimplantation Genetics Diagnosis Pgd Market Report:
In Europe, the PGD market is projected to rise from $0.62 billion in 2023 to $1.59 billion in 2033, supported by the favorable regulatory framework and increasing prevalence of genetic disorders necessitating advanced diagnostic tools.Asia Pacific Preimplantation Genetics Diagnosis Pgd Market Report:
The Asia-Pacific PGD market is projected to grow from $0.47 billion in 2023 to $1.21 billion in 2033, fueled by increasing healthcare expenditures, rising awareness of reproductive health, and growing adoption of advanced genetic testing techniques among healthcare providers.North America Preimplantation Genetics Diagnosis Pgd Market Report:
North America holds a substantial market share, expected to grow from $0.85 billion in 2023 to $2.18 billion by 2033, largely due to advanced healthcare systems, high levels of awareness about genetic testing, and increased funding for fertility treatments.South America Preimplantation Genetics Diagnosis Pgd Market Report:
The South American market is expected to increase from $0.23 billion in 2023 to $0.59 billion in 2033, driven by emerging healthcare infrastructure and an expanding patient base seeking fertility assistance and genetic services.Middle East & Africa Preimplantation Genetics Diagnosis Pgd Market Report:
The Middle East and Africa market is estimated to grow from $0.22 billion in 2023 to $0.57 billion in 2033, influenced by improving healthcare systems, alongside a growing number of fertility clinics and increased awareness of genetic testing.Request a custom research report for industry.
Preimplantation Genetics Diagnosis Pgd Market Analysis By Technique
Global Preimplantation Genetic Diagnosis (PGD) Market, By Technique Market Analysis (2023 - 2033)
In 2023, the market share of the Polymerase Chain Reaction (PCR) method is estimated at $1.60 billion and is anticipated to grow to $4.08 billion by 2033, holding a consistent market share of approximately 66.47%. Next Generation Sequencing (NGS) generates $0.63 billion in 2023, expected to expand to $1.60 billion by 2033, maintaining a 26.09% share. Microarray Technology represents a smaller segment, valued at $0.18 billion in 2023 and projected to reach $0.46 billion by 2033 with a 7.44% share.
Preimplantation Genetics Diagnosis Pgd Market Analysis By Application
Global Preimplantation Genetic Diagnosis (PGD) Market, By Application Market Analysis (2023 - 2033)
The applications of PGD are diversifying with Inherited Disorders projected to dominate at $1.25 billion (51.91% share) in 2023 and rise to $3.19 billion by 2033. Other segments include Gender Selection at $0.56 billion (23.4% share) in 2023, rising to $1.44 billion by 2033, followed by Cancer Prediction at $0.31 billion, expected to increase to $0.81 billion, holding a 13.12% share.
Preimplantation Genetics Diagnosis Pgd Market Analysis By Product Type
Global Preimplantation Genetic Diagnosis (PGD) Market, By Product Type Market Analysis (2023 - 2033)
Test Kits dominate the market, expected to grow from $2.07 billion (86.28% share) in 2023 to $5.30 billion by 2033. Services, while smaller, are also growing from $0.33 billion (13.72% share) in 2023 to $0.84 billion by 2033, reflecting an expanding service-based industry in PGD.
Preimplantation Genetics Diagnosis Pgd Market Analysis By End User
Global Preimplantation Genetic Diagnosis (PGD) Market, By End-User Market Analysis (2023 - 2033)
Hospitals lead the market with a significant share, projected to expand from $1.60 billion in 2023 to $4.08 billion by 2033, capturing a 66.47% market share. Fertility Clinics will grow from $0.63 billion (26.09% share) to $1.60 billion, signifying their increasing role in PGD. Research Institutes represent a smaller segment, moving from $0.18 billion to $0.46 billion, indicating a steady contribution to the industry from academic perspectives.
Preimplantation Genetics Diagnosis Pgd Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Preimplantation Genetics Diagnosis Pgd Industry
Illumina:
Illumina is a leading developer of life science tools and integrated solutions for the analysis of genetic variation and function, advancing PGD methodologies through innovative sequencing platforms.Thermo Fisher Scientific:
Thermo Fisher Scientific provides a diverse range of PGD solutions, leveraging advanced PCR and NGS technologies to cater to hospitals and fertility clinics.Natera:
Natera specializes in genetic testing and reproductive health solutions, particularly recognized for its non-invasive genetic testing approaches that enhance PGD capabilities.Gene by Gene:
Gene by Gene is renowned for its comprehensive genetic testing services and laboratory expertise, contributing significantly to the PGD market.We're grateful to work with incredible clients.
